Marc Rendell, MD is conducting a research study at the Creighton Diabetes Center.

This study is assessing the effectiveness of canagliflozin in preventing the worsening of diabetic kidney and heart disease in patients with type 2 diabetes and kidney disease.

We are looking for people who meet the following criteria:

1. People who have type 2 diabetes and are between 30 years old or older.
2. People with stage 2 or 3 chronic kidney disease and macroalbuminuria.

If you are interested in knowing more about this research study, please call (or e-mail):

Merideth Dunn
dunnwall@creighton.edu
(402) 280-4379

Stipend Available:

☑ Yes ☐ No

To find out more information about being a research participant, the benefits of participating in research at Creighton University, and your rights as a research participant, please visit Creighton’s Research Participant Information web page at http://www.creighton.edu/researchcompliance/humanresearchprotectionprogram/researchparticipantinformation/index.php.